The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment

Shi, Ming-Yan; Liu, Han-Ge; Chen, Xiaohong; Tian, Ye; Chen, Zhi‐Nan; Wang, Ke

doi:10.3389/fimmu.2022.1088886

Cited by 6 publications

(2 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that chemotherapy could induce antigen presentation and induce expression of immune checkpoints ( 23 ). In addition, chemotherapeutic agents-induced immunogenic cell death and their immune stimulation activity are considered the main mechanisms of combination therapy ( 24 ). Therefore, early initiation of immunotherapy may be beneficial in LANPC.…”

Section: Discussionmentioning

confidence: 99%

Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma

Yu,

Lu,

Wang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

PurposeTo investigate the treatment response and toxicity of the combination of induction chemotherapy (IC) and PD-1 inhibitor in locally advanced nasopharyngeal carcinoma (LANPC).MethodsPatients with stage III–IVA NPC who received IC or IC + PD-1 inhibitor were included. The chi-square test and multivariate logistic regression analysis were used for statistical analysis.ResultsA total of 225 patients were identified, including 193 (85.8%) and 32 (14.2%) who received IC alone and IC + PD-1 inhibitor, respectively. The addition of PD-1 inhibitor to IC significantly improved the tumor response than those treated with IC alone. The complete response (CR), partial response, stable disease, and progressive disease rates of 4.7% vs. 31.3%, 69.4% vs. 62.5%, 24.9% vs. 6.3%, and 1.0% vs. 0% in patients receiving IC alone and IC + PD-1 inhibitor, respectively (P<0.001). The results of the multivariate logistic regression showed that receiving PD-1 inhibitor was an independent predictor influencing the CR rate of patients (odds ratio 9.814, P<0.001). The most common toxicity by using IC and PD-1 inhibitor was hematological toxicity. In terms of non-hematological toxicity, 7 (21.9%) patients experienced thyroid dysfunction and all of them were hyperthyroidism. No grade 5 toxicities were found. In those who received IC and PD-1 inhibitor, the one-year locoregional recurrence-free survival, distant metastasis-free survival, disease-free survival, and overall survival were 100%, 96.9%, 96.9%, and 100%, respectively.ConclusionThe addition of PD-1 inhibitor to IC has promise as an effective treatment approach for LANPC. More studies are expected to provide further insights into the optimal use of this treatment strategy, paving the way for more personalized and effective treatment options for patients with LANPC.

show abstract

Section: Discussionmentioning

confidence: 99%

Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma

Yu,

Lu,

Wang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Patient responses to PD-1/PD-L1 blockade are not identical, and patients can be classified as responders, non-responders, and those who develop resistance based on their responses to anti-PD-1/PD-L1 antibodies 39 . As stated above, although anti-PD-1/PD-L1 antibodies exhibit potent antitumor effects in some patients, most patients do not benefit from PD-1/PD-L1 therapy due to primary or acquired treatment resistance 35 , 40 .…”

Section: Clinical Applications Of Pd-l1mentioning

confidence: 99%

Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy

Zhang¹,

Wu²,

Zhao³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

Programmed death-1 is a protein found on the surface of immune cells that can interact with its ligand, programmed death-ligand 1 (PD-L1), which is expressed on the plasma membrane, the surface of secreted cellular exosomes, in cell nuclei, or as a circulating soluble protein. This interaction can lead to immune escape in cancer patients. In clinical settings, PD-L1 plays an important role in tumor disease diagnosis, determining therapeutic effectiveness, and predicting patient prognosis. PD-L1 inhibitors are also essential components of tumor immunotherapy. Thus, the detection of PD-L1 levels is crucial, especially in the era of precision cancer therapy. In recent years, innovations have been made in traditional immunoassay methods and the development of new immunoassays for PD-L1 detection. This review aims to summarize recent research progress in tumor PD-L1 detection technology and highlight the clinical applications of PD-L1.

show abstract

Immunogenic cell death: A new strategy to enhancing cancer immunotherapy

Dou,

Fang,

Yang

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment

Cited by 6 publications

References 137 publications

Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma

Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma

Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy

Immunogenic cell death: A new strategy to enhancing cancer immunotherapy

Contact Info

Product

Resources

About